<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845689</url>
  </required_header>
  <id_info>
    <org_study_id>LMU-202-LTR</org_study_id>
    <nct_id>NCT00845689</nct_id>
  </id_info>
  <brief_title>Prevention of Liver Damage During Liver Surgery</brief_title>
  <acronym>LTR</acronym>
  <official_title>Study on the Potential Role of Intraoperative Hepatoprotection During Liver Resections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver damage as a consequnce of ischemia (I) and reperfusion (R) is known to harm the liver
      and could hence be a critical factor of the postoperative outcome of patients undergoing
      liver surgery. In order to protect the liver from ischemic damage following interventions
      such as the Pringle Maneuver, preconditioning has been successfully applied in various animal
      models as well as in humans. Since ischemia inevitably leads to cell hypoxia and subsequnet
      release of endogenuous metabolites, the investigators hypothesize that instead of brief
      periods of ischemia, the exogenuous infusion of purine analogues may also protect against
      subsequent prolonged periods of ischemia. Moreover, after reperfusion, the antiinflamamtory
      action of purine ananlogue infusion can further attenuated liver damage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>3</number_of_arms>
  <condition>Liver Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>liver resection with Pringle + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liver resection with Pringle + adenosine preconditiong</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>liver resection with Pringle + adenosine pre- and postconditioning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>NaCl 0,9 %</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine</intervention_name>
    <description>intravenous infusion of adenosine 0, 2 %</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adenosine</intervention_name>
    <description>intravenous infusion of adenosine 0,2 %</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver resection</intervention_name>
    <description>Liver resection with Pringle maneuver</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective resection of liver tumors

          -  age 18 to 80 years

          -  informed consent

        Exclusion Criteria:

          -  chronic obstructive pulmonary disease

          -  heart insufficiency NYHA III-IV

          -  atrio-ventricular conductance blockage II. (Mobitz) or III. degree

          -  atrial fibrillation

          -  coronary heart disease (CCS III. or IV. degree)

          -  arterial hypertension

          -  acute renal failure

          -  increased intracranial pressure

          -  gout

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>February 17, 2009</last_update_submitted>
  <last_update_submitted_qc>February 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Manfred Thiel</name_title>
    <organization>Department of Anaesthesiology of the Ludwig-Maximilians-University</organization>
  </responsible_party>
  <keyword>liver surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

